| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | ETS1; EWSR2; Protein C-ets-1; p54 |
| Entrez GeneID | 2113 |
| WB Predicted band size | Calculated MW: 50 kDa; Observed MW: 50 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | A synthetic peptide of human ETS1 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是3篇与ETS1抗体相关的文献摘要概览：
---
1. **"ETS1 regulates pathological angiogenesis and modulates endothelial cell response to VEGF"**
*作者：Liu et al., 2019*
摘要：本研究通过免疫组织化学(ETS1抗体)和ChIP-seq分析，揭示了ETS1在病理性血管生成中的关键作用。发现ETS1通过调控VEGF信号通路下游基因的表达，影响内皮细胞迁移和血管形成，为抗血管生成治疗提供潜在靶点。
---
2. **"ETS1 controls the development of CD4+ T cell lineages through transcriptional regulation"**
*作者：Muthusamy et al., 2016*
摘要：文章利用ETS1特异性抗体进行Western blot和流式细胞术，证明ETS1在调节CD4+ T细胞分化和自身免疫反应中的必要性。结果显示，ETS1缺失导致Th17细胞分化异常，加剧实验性自身免疫性脑脊髓炎(EAE)表型。
---
3. **"A novel monoclonal antibody for detecting ETS1 in formalin-fixed paraffin-embedded tissues"**
*作者：Zhang et al., 2021*
摘要：研究团队开发了一种高特异性的单克隆ETS1抗体(克隆号：3D6)，验证了其在福尔马林固定石蜡包埋(FFPE)组织中的适用性。该抗体成功应用于乳腺癌和结直肠癌样本，证实ETS1表达与患者预后不良相关。
---
4. **"ETS1 cooperates with β-catenin to drive colorectal cancer progression"**
*作者：Wang et al., 2018*
摘要：通过免疫共沉淀(ETS1抗体)和荧光素酶报告基因实验，研究发现ETS1与β-catenin形成复合物，协同激活Wnt靶基因，促进结直肠癌细胞侵袭和转移。研究为靶向ETS1-β-catenin轴的治疗策略提供了依据。
---
这些文献覆盖了ETS1抗体在基础机制研究、疾病模型和诊断工具开发中的应用。如需具体文献来源(期刊名称、卷期号等)，可进一步补充数据库检索关键词(如PubMed ID)。
The ETS1 antibody is a crucial tool in molecular biology research, targeting the ETS1 transcription factor encoded by the *ETS1* gene. ETS1 belongs to the ETS (E-twenty-six) family of DNA-binding proteins, which regulate gene expression by binding to purine-rich GGAA/T sequences in target promoters. First identified in the 1980s, ETS1 plays pivotal roles in immune regulation, angiogenesis, and cellular differentiation. Dysregulation of ETS1 is linked to cancers (e.g., leukemia, breast cancer), autoimmune diseases (e.g., lupus), and vascular disorders, making it a biomarker and therapeutic target.
ETS1 antibodies are widely used to detect ETS1 protein expression, localization, and interactions in techniques like Western blotting, immunohistochemistry (IHC), and chromatin immunoprecipitation (ChIP). Commercial ETS1 antibodies are often validated for specificity across human, mouse, and rat samples, with clones like D8O8T (Cell Signaling Technology) or sc-55581 (Santa Cruz Biotechnology) commonly cited. Researchers rely on these antibodies to study ETS1’s dual role as both an oncogene and tumor suppressor, depending on cellular context, and its interplay with pathways like MAPK/ERK.
Recent studies also explore ETS1’s involvement in epithelial-mesenchymal transition (EMT) and drug resistance. Proper validation via knockout controls or peptide blocking is critical, as cross-reactivity with other ETS family members (e.g., ETS2) may occur. Overall, ETS1 antibodies remain indispensable for unraveling its complex functions in health and disease.
×
